antibody

CD86 (Dendritic Cells Maturation Marker) Mouse Monoclonal Antibody

MBS438121

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

monoclonal

mouse

nonconjugated

[BU63]

human, mouse, rat

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, FACS

Antibody

CD86 (Dendritic Cells Maturation Marker) Mouse Monoclonal Antibody

[CD86]

[Activation B7-2 antigen; B lymphocyte activation antigen B72; CD28 antigen ligand 2; CD28LG2; CLS1; CTLA-4 counter-receptor B7.2; Early T-cell co-stimulatory molecule 1; ETC-1; FUN-1; LAB72; Ly-58; MB7-2; TS/A-2]

[T-lymphocyte activation antigen CD86 isoform 4; T-lymphocyte activation antigen CD86; T-lymphocyte activation antigen CD86; CD86 molecule; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD_antigen: CD86]

[CD86]

[CD86; CD86; B70; B7-2; B7.2; LAB72; CD28LG2; CD28LG2]

CD86_HUMAN

Monoclonal

IgG1, kappa

[BU63]

Mouse

Human, Mouse, Rat

217

Recognizes a protein of 70kDa, which is identified as CD86 (HLDA V; WS Code BP BP072. HLDA V; WS Code A A109. HLDA VI; WS Code BP 95. HLDA VI; WS Code B CD86.9). CD86 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily of cell surface receptors. It is expressed at high levels on resting peripheral monocytes and dendritic cells and at very low density on resting B and T lymphocytes. CD86 expression is rapidly upregulated by B cell specific stimuli with peak expression at 18 to 42 hours after stimulation. CD86, along with CD80/B71, is an important accessory molecule in T cell co-stimulation via its interaction with CD28 and CD152/CTLA4. Since CD86 has rapid kinetics of induction, it is believed to be the major CD28 ligand expressed early in the immune response. It is also found on malignant Hodgkin and Reed Sternberg (HRS) cells in Hodgkin's disease.

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Antibody with azide - store at 2-8°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Functional Studies, Flow Cytometry (FC/FACS), Immunofluorescence (IF), Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC) Formalin

Functional Studies (Order Ab without Azide). Flow Cytometry (1-2ug/million cells in 0.1ml). Immunofluorescence (0.5-1ug/ml). Western Blot (0.5-1ug/ml). Immunoprecipitation (0.5-1 -g/500ug protein Lysate). Immunohistology (Formalin-fixed) (2-4ug/ml for 30 minutes at RT) (Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris buffer with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes). Optimal dilution for a specific application should be determined.

Immunohistochemistry (IHC)

Flow Cytometry (FC/FACS

Flow Cytometry (FC/FACS)

Immunofluorescence (IF)

mmunofluorescencestaining of PFA fixed Ramos cells using CD86 Mouse Monoclonal Antibody (BU63) followed by goat anti-mouse IgG conjugated to CF488 (green). Nuclei are stained with Reddot.

SDS-PAGE

SDS-PAGE Analysis Purified CD86 Mouse Monoclonal Antibody (BU63) Confirmation of Integrity and Purity of Antibody.

Cellular Localization: Cell Surface. Immunogen: ARH-77 (B-lymphoblastoid cell line)

Hu-Chromosome Location: 3q13.33. Positive Control: 293T or Jukat cells. Monocytes and dendritic cells, activated T, B and natural killer cells in lymph node or tonsil.

Engel P et. al. Blood. 1994;84(5):1402-7.Caux C et. al. J Exp Med. 1994;180(5):1841-7. Mauri D et. al. J Immunol. 1995;155(1):118-27.Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997)

332634950

NP_001193853.1

NM_001206924.1

P42081

70kDa

Adaptive Immune System Pathway (1269171); Allograft Rejection Pathway (920963); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); CD28 Co-stimulation Pathway (1269178); CD28 Dependent PI3K/Akt Signaling Pathway (1269179); CD28 Dependent Vav1 Pathway (1269180); CTLA4 Inhibitory Signaling Pathway (1269181)

This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in several transcript variants encoding different isoforms.[provided by RefSeq, May 2011]

CD86: Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T- cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. 4 isoforms of the human protein are produced by alternative splicing. Protein type: Immunoglobulin superfamily; Membrane protein, integral. Chromosomal Location of Human Ortholog: 3q21. Cellular Component: cell surface; integral to membrane; plasma membrane. Molecular Function: phosphatidylinositol-4,5-bisphosphate 3-kinase activity; protein binding; receptor activity. Biological Process: cell-cell signaling; immune response; phosphoinositide-mediated signaling; positive regulation of cell proliferation; regulation of phosphoinositide 3-kinase cascade; T cell activation; T cell costimulation

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

0.1 mg (With BSA & Azide at 0.2mg/ml)

340

0.1 mg (Without BSA & Azide at 1mg/ml)

340